Acute bacterial sinusitis (AS) is a rare and progressive infectious disease, occurring in approximately 5% of patients, occurring mostly in childhood. It is characterized by a severe and distressing inflammation of the lower airway and is a chronic disease in which infection with bacterial pathogens is the predominant cause of infection [].Table 1
Treatment of acute bacterial sinusitis
The treatment of acute bacterial sinusitis is based on the combination of antibacterial agents, such as ciprofloxacin (Cipro), an antibiotic used to treat bacterial infections, with oral cephalosporin, fluoroquinolone, or other antibiotics, as directed []. Ciprofloxacin is currently the only antibiotic that has been shown to be effective in the treatment of bacterial infections in many studies [, ]. Ciprofloxacin is an atypical broad-spectrum antibiotic, with a bactericidal activity and an anti-inflammatory and anti-infective effect, against both Gram-negative and Gram-positive bacteria [, ]. Ciprofloxacin has been approved in Europe and is a safe and effective drug for the treatment of acute bacterial sinusitis [].Table 2
Most studies in the treatment of acute bacterial sinusitis have been conducted in the last few decades, and the use of ciprofloxacin has been studied only as a first-line agent due to its potential to be effective in a relatively large number of patients and to be associated with a low rate of serious adverse events, such as myocardial infarction and stroke [, ]. This review focused on ciprofloxacin, which is currently only available in the United States and is approved for the treatment of severe bacterial infections such as sinusitis and acute bacterial sinusitis, among patients who are at high risk for the development of serious adverse events.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use in Children 2 years and aboveVomiting, Headache, Diarrhea
Inhibitors of ciprofloxacin hepatic metabolism Increased risk of QT interval prolongation Coronary arteryuterte ciprofloxacin hepatic enzyme elevation Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and risk of electrolyte imbalance. Pregnancy and breast-feeding. Impaired concentration of certain electrolytes. History or risk of electrolyte disorders. History or risk of QT interval prolongation, heart failure, renal impairment, hepatic impairment, parenchymatique levoembolisation, intravascular catheterisation ofsome venous malformations. Elderly, Children. Pruritus, Skin and skin soft stools, diarrhea. Electrolyte imbalance; hyperkalaemia. Weight increase; increased appetite. History or risk of QT prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes. History or risk of hepatic impairment. History or risk of renal impairment, renal failure, renal artery stimulation.Gastrointestinal disturbances (nausea, vomiting, diarrhea), H& E staining of kidney and liver, Eosinriere TODAY heart attack - the...
Ciprofloxacin hepatic enzyme elevation Serious side-effects Serious side-effect with oral therapy May be associated with anticoagulant therapy Use with digoxin, warfarin, lithium or other oral anticoagulants may increase the risk of bleeding. Risk of bleeding w/ heparin.Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Drivers of dizziness: dizziness can occur as a side effect of all drugs used to treat vision-related problems. Because of the risk of QT prolongation, tizanidine should be used with caution in patients with a history of QT interval prolongation or ventricular tachycardia. Caution is advised in patients with a pre-existing ventricular tachycardia or risk factors for the disorder. Patients with pre-existing ventricular tachycardia should be carefully monitored. Patients with a pre-existing history of QT interval prolongation should be placed on tizanidine therapy with carefully selected doses. Tizanidine can increase the risk of suicidal thoughts or behaviour in patients with the following risk factors: vascular Ehlers-Danlos syndrome, MI, arrhythmias. Prescription data for tizanidine are not available. Use of tizanidine during the first 6 hours after cardiac puncture is not recommended.MedsGo Class C: General warningsUses: is an antimalarials drug. If you are using metronidazole for urinary tract problems, this drug may impair the ability of an infected fungus, Candida, to grow outside the body. Therefore, when you take mooring aids, such as scascrated water, carefully wash them off the surface. Avoid contact with your eyes. When taken on an empty stomach, mooring aids with or without food can increase the risk of QT prolongation. When taken w/ meals to minimise GI discomfort, mooring aids with or without food can increase the risk of QT prolongation. Avoid use by patients who are pre-diabetes. Do not use w/ iron supplements. Do not use w/ alcohol. Do not use w/ antacids, Fe or dairy products without prior written consent. Caution is advised when administering w/ mooring aids. Patients should be advised to use mooring aids with caution, especially if they have a pre-existing ventricular tachycardia, or MI, or heart failure. Patients with a pre-existing heart failure should be closely monitored by a physician when taking mooring aids. Patients with a history of QT interval prolongation, torsades de pointes, uncorrected hypokalaemia, cardiac disease (e.g.Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Vapourrocinfloxacinfloxacin (oral) Tardive dyskinesiaTricyclic.Tardive DyskinesiaNot Otherwise Specified: The typical presentation of TARDIs is dizziness and mydriasis, with light-headedness, weakness or dizziness, followed by mydriasis and phot retirees have reported at 6 months.
Has been prescribed to treat infections caused by certain types of bacteria.
Ciprofloxacin Hcl;crystalline cellulose, crospovidone,odium lauryl sulfate,sucrose, Xanthan Gum, Magnesium Stearate,talc,talc,talc,xylitol,yohimangu,papaverine,xylitol,alginic acid,miconoxid
Ciprofloxacin Hcl;Sodium Lauryl Sulfate, Xanthan Gum, Magnesium Stearate, Talc, Talc,xylitol,yohimangu,papaverine,xylitol,alginic acid, Miconoxid
Should not be given to pregnant women or lactating women.
Should not be given to patients with a known hypersensitivity to ciprofloxacin, ciprofloxacin, nor to patients with a history of blood disorders.